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Abstract
Background: Human papillomavirus (HPV), especially HPV16, is associated with the development of both cervical and
tonsillar cancer and intratype variants in the amino acid sequence of the HPV16 E6 oncoprotein have been demonstrated to
be associated with viral persistence and cancer lesions. For this reason the presence of HPV16 E6 variants in tonsillar
squamous cell carcinoma (TSCC) in cervical cancer (CC), as well as in cervical samples (CS), were explored.
Methods: HPV16 E6 was sequenced in 108 TSCC and 52 CC samples from patients diagnosed 2000–2008 in the County of
Stockholm, and in 51 CS from young women attending a youth health center in Stockholm.
Results: The rare E6 variant R10G was relatively frequent (19%) in TSCC, absent in CC and infrequent (4%) in CS, while the
well-known L83V variant was common in TSCC (40%), CC (31%), and CS (29%). The difference for R10G was significant
between TSCC and CC (p=0.0003), as well as between TSCC and CS (p=0.009). The HPV16 European phylogenetic lineage
and its derivatives dominated in all samples (.90%).
Conclusion: The relatively high frequency of the R10G variant in TSCC, as compared to what has been found in CC both in
the present study as well as in several other studies in different countries, may indicate a difference between TSCC and CC
with regard to tumor induction and development. Alternatively, there could be differences with regard to the oral and
cervical prevalence of this variant that need to be explored further.
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Introduction
Infection with high-risk (HR) human papillomaviruses (HPV)
has since the beginning of 1980s been recognized to cause the
development of cervical cancer and more recently also oropha-
ryngeal cancer [1,2]. Among oropharyngeal cancers mainly
tonsillar and base of tongue cancers are associated with HPV.
Notably, the incidence of HPV positive oropharyngeal cancer has
increased during the last decades, both in Europe and the US [3–
5]. According to Swedish Cancer Registry, in Sweden, presently
over 400 new cases of cervical cancer and around 200 cases of
tonsillar cancer are diagnosed every year.
All HPV types known to be associated with oropharyngeal
cancer are also linked to cervical cancer and HPV16 dominates in
both, causing 50–60% of all HPV positive cervical cancer and
roughly 90% of all HPV positive tonsillar cancer. In addition,
while the HPV genome is mostly integrated in cervical cancer, it is
often episomal in tonsillar cancer [6]. This indicates that, although
there are many similarities between these two tumor types there
could also be differences, both with regard to the potential of
HPV16 to cause tumor development, and to the way different
HPV types cause tumors.
Variants of the HPV16 genome in cervical cancer, in pre-stages
of cervical cancer, and in cervical samples from different
geographical areas have been studied extensively and HPV has
been classified into phylogenetic lineages as European (E), Asian
(As), Asian-American (AA), African-1 and -2 (Af-1 and Af-2), and
North American1 (NA1) [7–11].
The major transforming proteins of HPV16, E6 and E7, target
p53 and Rb respectively, inhibit apoptosis and promote prolifer-
ation and therefore most studies on HPV16 variants have focused
on E6 and E7 in addition to the studies of the non-coding control
region (NCCR). Variants have been shown to often differ in E6
and NCCR, while the E7 protein is often more conserved [12,13].
In addition, to the major variant lineages, variants with single
nucleotide alterations are frequently found, especially in tumors.
The most frequent of these mutations is the T to G transition at nt
350 in E6, abbreviated as E-T350G, causing an amino acid
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on the L83V variant have demonstrated an association with viral
persistence and cancer progression of cervical carcinoma, although
some later studies have failed to confirm this association [14–17].
Other variants have also been linked to properties important for
tumor development such as e.g. those with the ability to inhibit
p53 transactivation [18].
While many studies on HPV16 variants have been performed in
cervical cancer, very few studies of this kind have been made in
head neck cancer [19,20]. The purpose of this study was to
therefore to examine if there were any differences in occurrence
and frequency of HPV16 E6 variants between tonsillar cancer and
cervical cancer. For this reason the prevalence of HPV16 E6
sequences were compared in cervical and tonsillar cancer samples
from patients diagnosed during the same time frame in the County
of Stockholm, Sweden. In addition, to compare the data obtained
from these tumors with the frequencies of HPV16 variants in
healthy persons, HPV16 E6 was also analyzed in cervical samples
from healthy young women at a youth clinic in Stockholm.
Results
HPV16 E6 variants at amino acid R10G and L83V
Fifty-five HPV16 positive TSSC, 52 CC and 51 CS were
analyzed with regard to HPV16 E6 sequence, Table S1. The most
remarkable difference between TSCC and CC was found with
regard to the frequencies of the E-A131G variant causing a change
from arginine to glycine in a.a. 10 (R10G). This mutation was
present in 22% (12/55) of TSCC, while completely lacking in the
CC samples and only present in 4% (2/51) of cervical samples.
This difference was significant both between TSCC and CC
(p=0.0003) as well as between TSCC and CS (p=0.009).
The E-T350G variant was the most common one among all the
three groups of samples. This variant, causing a shift from leucine
to valine in aa 83 (L83V), was especially common in TSCC (45%)
followed by CC (31%) and CS (29%) respectively.
Validation of R10G and L83V frequencies in further TSCC
samples
To further validate the increased frequencies of R10G and
L83V mutations in TSCC, 53 additional TSCC samples, from
patients diagnosed at the same hospital during the same period,
were evaluated only for the R10G and L83V mutations. Among
these 53 samples 17% (9/53) carried the R10G and 34% (18/53)
the L83V mutation. When all the 108 samples were summarized
19% had R10G and 40% the L83V mutation. The majority (12/
21) of the E6 from TSCC harboring R10G also contained L83V.
No significant difference was observed between the originally
selected 55 TSCC and the extended TCCS group with regard to
these two mutations.
Frequency of other variants
Mutations at other sites were less common for all types of
samples, and only 19/28 of these affected the amino acid
sequence. The most common were Q14H and H78Y, both
present in 4% of CC and CS, while 7% of TSCC had Q14H and
H78Y. In addition, two cervical cancer samples had 27 bp repeats
between nt 528 and 554.
Distribution of different phylogenetic lineages
As detailed in Table S1, the HPV16 E6 European prototype
was found in 38% of TSCC, 65% of CC and 59% of CS.
However, when samples with the European type containing minor
nucleotide differences (including R10G and L83V) were included,
these figures increased to 93, 94 and 96% respectively. As also
shown in the Table S1 other types, African-1 and 2, East Asian.
Asian American and North American were only found in few
samples.
Correlation of HPV16 E6 variants in tonsillar cancer with
clinical parameters
The TSCC samples were compared with regard to patient and
tumor characteristics based on the presence of R10G, L83V or
absence of these variants as presented in Table 1. There were
however no significant differences for any of these parameters,
although there was a tendency for tumors with R10G to have a
lower T stage.
The presence of the R10G or L83V variants in tonsillar cancer
was analyzed in correlation to the 3-year disease-free survival
(DSF) of the patients. However, no significant correlation was
found when DSF was compared between patients with presence or
absence of the R10G variant or between patients with presence or
absence of the L83V variant (data not shown).
Discussion
In the present study, we have analyzed and compared the
frequency of different HPV16 E6 variants in TSCC, CC and CS,
all obtained from the Stockholm area during the same time period.
We found that HPV16 R10G was relatively common in TSCC,
absent in CC and rare in CS. The HPV 16 European lineage was
dominating and the L83V variant was very common in all three
categories of samples.
The fact that the otherwise rare HPV16 E6 variant R10G was
observed in TSCC, but not in CC in patients diagnosed at the
same time period from the same hospital is striking. This variant
has to our knowledge always been rare, although observed in CC
in some other studies [11,13,18]. Though the time from HPV
infection to the development of tonsillar cancer is unknown it is
likely similar between cervical and tonsillar cancer, since the
median age of the patients is comparable. Thus, it is reasonable to
assume that the patients in this study with cervical and tonsillar
cancer were most likely infected with HPV16 during approx-
imately the same period. The reason for the high frequency of
R10G variant in TSCC from Stockholm, as compared to CC from
both Stockholm and other areas, is unknown. One possibility is
that this HPV16 variant for some reason was/is more common in
the oral as compared to the genital area. Further studies on
HPV16 obtained from oral samples are needed to explore this
possibility. Another possibility could be that this variant of HPV16
has a higher propensity to cause TSCC. Notably, although the
majority of patients with TSCC were men, and only women have
CC, there were no sex-related differences in the relative
frequencies of R10G in TSCC. The collected data indicate that
virtually all patients carrying the R10G variant had Sweden as
their country of origin, however we do not have information if
they have moved to Stockholm from other parts of Sweden.
It is well established that HPV16 E6 together with E6AP (E6-
associated protein) forms a complex that specifically targets p53
and mediate p53 degradation, which is essential for tumorigenesis
[21,22]. Several studies have been performed on the R10G variant
in cervical cancers. The R10G mutation is in the N-terminal end,
important for p53 binding and degradation, and it has also been
shown to result in a modified B/T cell epitope [13,23,24]. It has
been demonstrated that both E6 with R10G and L83V retain the
ability to abrogate growth arrest, and strongly reduce the steady
state levels of p53 [25]. However, while E6 with R10G has a
decreased binding to E6BP (E6-binding protein) and reduced
HPV16 E6 R10G Variant in Tonsillar Cancer
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increased binding to E6BP and retained ability to induce Bax
degradation compared to prototype HPV16 E6 [18]. E6 with both
the R10G and L83 alteration, which 9/12 TSCC had in this
study, behaved similar to the prototype [18]. In addition, the
R10G site has also been reported to be essential for nuclear
localization signal [26]. Thus, several different features of the
R10G site may influence cancer progression, even though it is
unclear to what degree. In the present study no significant
difference was observed with regard to the 3-year disease-free
survival among the patients with TSCC carrying or not carrying
HPV16 E6 R10G variant. This argues against the possibility that
this variant would cause more aggressively growing TSCC.
Other variants of HPV16 E6, especially L83V, differ geograph-
ically and may affect the pathological risk [27]. In this study, L83V
was the most common variant in all types of material, which is in
line with many other observations both in the genital and head
and neck region [16,19,20,28,29]. Here, a higher prevalence of
L83V was found in TSCC compared to CC and CS, while the
prevalence in the latter categories were roughly in agreement with
previous reports[12,14,29–31]. There are however several studies
demonstrating an association between L83V and increased virus
persistence, and risk of cervical neoplasia and cancer progression
[28,32]. Furthermore, studies on HPV16 E6 variants and the
cellular immune response indicate specific changes, that from a
host-virus immunology point of view may explain a modified
oncogenic potential [33–35]. Noteworthy, we did not find any
significant correlation between the presence or absence of the
L83V variant and the 3-year disease free survival of the patients.
It is noteworthy that the European HPV16 variant clearly has
about the same very high frequency in CS from young women,
obtained 2009–2010, as in CC samples. With the increase in
travelling during the last decades an increase in HPV16 variants
from other geographical areas would not have been unexpected,
but no such increase was observed.
A limitation in the present study is the number of analyzed
samples. Nevertheless, the 108 TSCC analyzed constitute
approximately 65% of all patients from the County of Stockholm
with HPV16 positive TSCC diagnosed during this time frame and
where biopsies were available [1,36]. Another limitation is that
only the E6 region was analyzed. Thus, if there were any
differences in the NCCR, E7 or E5 regions between the TSCC
and CC samples, these would have been missed.
In this study we found a significant difference in the distribution
of HPV16 variants between TSCC and CC samples from patients
admitted to the same hospital during the specific time period.
More specifically, the rare R10G variant was significantly more
common in TSCC than in CC, and was frequently in combination
with the L83V variant in the former tumors. Further studies are
needed to investigate if the R10G variant may be more common
in oral as compared to cervical samples. In addition, there was
relative concordance between the presence of variants in CC and
CS.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee at
Karolinska Institutet, Stockholm, Sweden, according to the ethical
permissions 2005/431-31/4, 2005/1330-32, 2008/870-31/4,
2008/813-31/2 and 2009/1278-31/4. Written informed consent
was obtained from all participants in the study.
Tumor and cervical samples material
Pre-treatment paraffin embedded tumour biopsies from patients
from the County of Stockholm, diagnosed 2000–2007, with
tonsillar squamous cell carcinoma (TSCC) or 2003–2008 with
cancer of the uterine cervix (CC). All tumor samples had
previously been analyzed for the presence and type of HPV
[1,36–38]. Among the 166 TSCC and 90 CC that were HPV16
positive, 55 TSCC and 52 CC were randomly selected. In the
second part of the study, for validation, 53 additional, randomly
selected, HPV16 positive TSCC from the same time frame were
included. A flow chart for the TSCC samples is presented in
Figure 1. In addition, 51 HPV16 positive cervical samples (CS),
from a previous study from 2009–2010 at a youth health center in
Stockholm [39] were randomly selected and analyzed. The mean
ages of the cancer patients were 59.7 y (median 59 y, range 30–
84 y) for TSCC patients and 50.3 y (median 45 y, range 25–88 y)
for CC patients while the mean age for the women at the youth
clinic was 19.9 y (median 20 y, range16–22 y).
Sequencing
DNA was extracted and analyzed for the presence of HPV and
HPV type as described in previous studies [1,37,39]. For the
analysis of HPV16 E6 from cancer tissues two primer pairs
covering the whole E6 region was utilized. 59- CCGGTTAGTA-
TAAAAGCAGACAT-39 together with 59-TGCTGTTCTA-
ATGTTGTTCC-39 amplifying bp 57–375 and 59- GGAATC-
CATATGCTGTATGT-39 together with 59- TGCAATG-
TAGGTGTATCTCC-39 amplifying bp 273–587. For cervical
samples one primer pair covering the whole of E6 was utilized; 59-
CCGGTTAGTATAAAAGCAGACAT-39 and 59-GTACC-
CTCTTCCCCATTGGT-39 amplifying bp 57–902. PCR was
performed with annealing temperature at 49uC and products were
purified using ExoSAP-IT (USB,VWR) according to the protocol
of the manufacturer. A PCR for sequencing was performed on the
purified products with Big Dye
TM terminator (Applied biosystems)
and the amplicons were analyzed in an Applied Biosystems 3130
sequencer. Both DNA strands were sequenced and the DNA
sequence and corresponding amino acid sequence was compared
with the reference European HPV16 sequence (reference code:
NC_001526.1) using the Sci-Ed software (Science and Educational
Figure 1. Flow chart showing the tumors from patients
diagnosed with TSCC in the County of Stockholm 2000–2007
and the TSCC selected for inclusion in the study.
doi:10.1371/journal.pone.0036239.g001
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MS) were involved in the analysis of the sequences. For cases
where the result obtained was unclear, the sequencing was
repeated.
Statistical analysis
Differences in frequencies of variants for TSCC and CC or CS
were evaluated by chi-square and Fischer’s exact test (two-tailed)
using on-line statistical analysis software (GraphPad Software).
Mean age was the age at the first diagnosis.
Disease-free survival (DFS) was defined as time from the date of
diagnosis to the date of the last known occasion that the patient
was disease-free, or the date of disease recurrence (local, regional
or distant recurrence). Death without documented recurrence was
censored at the date of death. Cumulative survival was calculated
with the Kaplan-Meier method and analyzed with the log-rank
test. Analysis of survival was performed in SPSS (IBM SPSS
Statistics, version 20).
Supporting Information
Table S1 The frequencies of different HPV16E6 variants in
cervical cancer (CC), tonsillar squamous cell carcinoma (TSCC)
and cervical samples (CS).
(DOC)
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